IMPORTANT: The full content of this page is available to premium users only.
Friday, August 1, 2014
Volume:
30
Issue:
8
Abstract:
On May 14, 2014, Chinese police announced they had charged Mark Reilly, the former head of GlaxoSmithKline PLC’s China unit, and other colleagues with corruption, after an investigation determined the firm made billions of yuan from elaborate schemes to bribe doctors and hospitals.[1]